Matches in SemOpenAlex for { <https://semopenalex.org/work/W2146064654> ?p ?o ?g. }
- W2146064654 endingPage "3129" @default.
- W2146064654 startingPage "3124" @default.
- W2146064654 abstract "Purpose To evaluate the outcome of patients with limited-stage small-cell lung cancer (L-SCLC) treated with cisplatin and etoposide (PE), early prophylactic cranial irradiation (PCI), and high-dose twice-daily thoracic radiotherapy (bid RT). Patients and Methods A total of 76 assessable patients were treated on this phase II trial, which included six cycles of PE. PCI (25 Gy/10 fractions) was delivered during cycle 3 to responding patients. Cycles 4 and 5 included concurrent chemotherapy and thoracic RT (30 Gy/20 bid fractions, a 2-week break, and another 30 Gy/20 bid fractions). Results Of the 76 assessable patients, 74 patients (97%) suffered grade 3 or greater (3+) toxicity and 61 patients (80%) had grade 4 or greater (4+) toxicity. Of these adverse events, grade 3+ hematologic toxicity occurred in 72 patients (95%), and grade 3+ nonhematologic toxicity occurred in 55 patients (72%). Only one (2%) of the 61 patients who received PCI experienced treatment failure in the brain. The 5-year survival rate of the 76 assessable patients was 24% (median, 20 months). The 5-year survival rate of the 64 patients who received thoracic RT was 29% (median, 22 months). The 5-year cumulative incidence of in-field treatment failure was 34%. Conclusion This regimen included a high total dose of bid TRT, which resulted in a favorable 5-year survival rate. Local failure remains a problem that will require additional investigation. Newer technology should allow the safe administration of greater doses of RT, which should improve patient outcome. Data from eight trials were combined to demonstrate a relationship between RT dose fractionation and 5-year survival." @default.
- W2146064654 created "2016-06-24" @default.
- W2146064654 creator A5004092928 @default.
- W2146064654 creator A5007505775 @default.
- W2146064654 creator A5013854802 @default.
- W2146064654 creator A5015875841 @default.
- W2146064654 creator A5021990576 @default.
- W2146064654 creator A5031000802 @default.
- W2146064654 creator A5041114807 @default.
- W2146064654 creator A5051786877 @default.
- W2146064654 creator A5055648300 @default.
- W2146064654 creator A5060104863 @default.
- W2146064654 creator A5078543517 @default.
- W2146064654 creator A5091659110 @default.
- W2146064654 date "2007-07-20" @default.
- W2146064654 modified "2023-09-23" @default.
- W2146064654 title "Results of a Phase II Study of High-Dose Thoracic Radiation Therapy With Concurrent Cisplatin and Etoposide in Limited-Stage Small-Cell Lung Cancer (NCCTG 95-20-53)" @default.
- W2146064654 cites W1905406155 @default.
- W2146064654 cites W1963592300 @default.
- W2146064654 cites W1964402113 @default.
- W2146064654 cites W1965125352 @default.
- W2146064654 cites W1971747664 @default.
- W2146064654 cites W1973510243 @default.
- W2146064654 cites W1982172413 @default.
- W2146064654 cites W1992291788 @default.
- W2146064654 cites W2004764331 @default.
- W2146064654 cites W2011868684 @default.
- W2146064654 cites W2021987821 @default.
- W2146064654 cites W2096555825 @default.
- W2146064654 cites W2121774591 @default.
- W2146064654 cites W2124353451 @default.
- W2146064654 cites W2127093828 @default.
- W2146064654 cites W2160012348 @default.
- W2146064654 cites W2323020638 @default.
- W2146064654 cites W2339444986 @default.
- W2146064654 cites W2341745217 @default.
- W2146064654 doi "https://doi.org/10.1200/jco.2006.09.9606" @default.
- W2146064654 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17634491" @default.
- W2146064654 hasPublicationYear "2007" @default.
- W2146064654 type Work @default.
- W2146064654 sameAs 2146064654 @default.
- W2146064654 citedByCount "55" @default.
- W2146064654 countsByYear W21460646542012 @default.
- W2146064654 countsByYear W21460646542013 @default.
- W2146064654 countsByYear W21460646542014 @default.
- W2146064654 countsByYear W21460646542015 @default.
- W2146064654 countsByYear W21460646542016 @default.
- W2146064654 countsByYear W21460646542017 @default.
- W2146064654 countsByYear W21460646542018 @default.
- W2146064654 countsByYear W21460646542019 @default.
- W2146064654 countsByYear W21460646542020 @default.
- W2146064654 countsByYear W21460646542021 @default.
- W2146064654 countsByYear W21460646542022 @default.
- W2146064654 crossrefType "journal-article" @default.
- W2146064654 hasAuthorship W2146064654A5004092928 @default.
- W2146064654 hasAuthorship W2146064654A5007505775 @default.
- W2146064654 hasAuthorship W2146064654A5013854802 @default.
- W2146064654 hasAuthorship W2146064654A5015875841 @default.
- W2146064654 hasAuthorship W2146064654A5021990576 @default.
- W2146064654 hasAuthorship W2146064654A5031000802 @default.
- W2146064654 hasAuthorship W2146064654A5041114807 @default.
- W2146064654 hasAuthorship W2146064654A5051786877 @default.
- W2146064654 hasAuthorship W2146064654A5055648300 @default.
- W2146064654 hasAuthorship W2146064654A5060104863 @default.
- W2146064654 hasAuthorship W2146064654A5078543517 @default.
- W2146064654 hasAuthorship W2146064654A5091659110 @default.
- W2146064654 hasConcept C126322002 @default.
- W2146064654 hasConcept C141071460 @default.
- W2146064654 hasConcept C197934379 @default.
- W2146064654 hasConcept C2776256026 @default.
- W2146064654 hasConcept C2776694085 @default.
- W2146064654 hasConcept C2778119113 @default.
- W2146064654 hasConcept C2779562246 @default.
- W2146064654 hasConcept C2781047374 @default.
- W2146064654 hasConcept C2781413609 @default.
- W2146064654 hasConcept C2911091166 @default.
- W2146064654 hasConcept C29730261 @default.
- W2146064654 hasConcept C31760486 @default.
- W2146064654 hasConcept C45393284 @default.
- W2146064654 hasConcept C500558357 @default.
- W2146064654 hasConcept C509974204 @default.
- W2146064654 hasConcept C71924100 @default.
- W2146064654 hasConcept C88879693 @default.
- W2146064654 hasConceptScore W2146064654C126322002 @default.
- W2146064654 hasConceptScore W2146064654C141071460 @default.
- W2146064654 hasConceptScore W2146064654C197934379 @default.
- W2146064654 hasConceptScore W2146064654C2776256026 @default.
- W2146064654 hasConceptScore W2146064654C2776694085 @default.
- W2146064654 hasConceptScore W2146064654C2778119113 @default.
- W2146064654 hasConceptScore W2146064654C2779562246 @default.
- W2146064654 hasConceptScore W2146064654C2781047374 @default.
- W2146064654 hasConceptScore W2146064654C2781413609 @default.
- W2146064654 hasConceptScore W2146064654C2911091166 @default.
- W2146064654 hasConceptScore W2146064654C29730261 @default.
- W2146064654 hasConceptScore W2146064654C31760486 @default.
- W2146064654 hasConceptScore W2146064654C45393284 @default.
- W2146064654 hasConceptScore W2146064654C500558357 @default.
- W2146064654 hasConceptScore W2146064654C509974204 @default.